Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …

Antiviral drug resistance is a matter of great clinical importance that, historically, has been
investigated mostly from a virological perspective. Although the proximate mechanisms of …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

BACKGROUND & AIMS: The GLOBE trial has compared the efficacy and safety of
telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B …

Background Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a
key therapeutic goal for chronic hepatitis B. Methods In this double-blind, phase 3 trial, 1370 …

Substantial advances have been made in the treatment of chronic hepatitis B in the past
decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and …

Abstract 360 million people are chronically infected with the human hepatitis B virus (HBV)
and are consequently prone to develop liver cirrhosis and hepatocellular carcinoma. As …

Chronic hepatitis B (CHB) is an important public health problem worldwide and in the United
States, with approximately 25% of patients infected as neonates dying prematurely from …

BACKGROUND & AIMS:: Long-term treatment with entecavir resulted in durable virologic
suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B …

An international group of experienced hepatologists and virologists conducted a single-day
workshop to review the management of patients with chronic hepatitis B receiving treatment …